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Case Report
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The current standard of care (SoC) for chronic hepatitis C,
i.e. the combination of a pegylated-interferon (PEG-IFN) with
ribavirin (RBV), may activate underlying autoimmune condi-
tions. Particularly, interferon (IFN) has been known to induce
or exacerbate autoimmune hepatitis (AIH) and primary
biliary cirrhosis (PBC) in hepatitis C virus patients. We
describe a severe, acute-onset antimitochondrial antibody
(AMA)-M2 positive AIH appearing during the last weeks of
SoC in a woman with chronic hepatitis C and no previous
history of autoimmunity, and resolving on protracted ste-
roids. In this context, the relevance of the characterization
of the immunoglobulin isotype of portal plasma cells for a
more appropriate diagnosis of autoimmune liver diseases
can be emphasized.
INTRODUCTION
THE CURRENT STANDARD of Care (SoC) forchronic hepatitis C, i.e. the combination of a
pegylated-interferon (PEG-IFN) with ribavirin (RBV),1
may activate underlying autoimmune conditions such
as thyroiditis2 or systemic lupus erythematosus.3 Par-
ticularly, interferon (IFN) has been known to induce or
exacerbate autoimmune hepatitis (AIH)4–10 and primary
biliary cirrhosis (PBC)11,12 in hepatitis C virus (HCV)
patients. We describe a severe, acute-onset antimito-
chondrial antibody (AMA)-M2 positive AIH appearing
during the last weeks of SoC in a woman with chronic
hepatitis C and no previous history of autoimmunity,
and resolving on protracted steroids.
CASE REPORT
AN ASYMPTOMATIC 20-year old Caucasian woman(height 160 cm, weight 57 kg, body mass index
[BMI] 22.3 kg/m2) with chronic hepatitis C (HCV geno-
type 1b, HCV RNA 1 170 000 IU/mL) underwent a liver
biopsy in July 2005 as part of her diagnostic workup
before receiving SoC. At the time of biopsy (see Table 1)
alanine aminotransferase (ALT) was twice the upper
limit of normal (u.l.n.) while g-glutamiltransferase
(GGT), alkalyne phosphatase (AP) and bilirubin were
normal. Non-organ specific autoantibodies (NOSAs,
tested by indirect immunofluorescence for antinuclear
antibody (ANA), AMA, SMA and by immunoblotting for
AMA type M2, liver kidney/microsome type 1 [LKM-1],
LC1, soluble liver antigen/liver pancreas [SLA/LP]) were
negative. At biopsy a pattern of mild chronic hepatitis
(grade 2/3, stage 1/4 according to Scheuer’s classifica-
tion) and no sign of PBC or AIH were evidenced
(Fig. 1a). Immunohistochemistry for cytokeratin 7 (CK7
antibody, clone OV-TL12/30, Dako; Dako A/S, Glos-
trup, Denmark) highlighted the presence of normal
portal bile ducts, without reactive bile duct proliferation
(Fig. 1b). The intrahepatic immunoglobulin (Ig) IgG/
IgM plasma cells assessment (polyclonal anti-IgG and
anti-IgM; Novocastra, Newcastle, United Kingdom)
showed a low number of portal plasma cells with an
IgM plasma cell number < 4/portal tract (Fig. 1c).
An intended course of 48 weeks of SoC (PEG-IFN
a-2b 1.5 mg/kg per week; RBV 1000 mg/day) was started
in September 2005. HCV-RNA was undetectable
(<50 IU) at week 4 and week 12, and all liver tests were
normal at week 12. At week 42 a slight rise of AST (2 x
u.l.n.) and ALT (1.5 x u.l.n.) was noted. GGT, AP and
bilirubin were normal, and HCV-RNA still negative.
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Therapy was stopped at week 48 in August 2006. At the
time of stopping, AST and ALT were nine and 11 times
the u.l.n., GGT seven times the u.l.n., AP 2.5 times the
u.l.n., total bilirubin 6.1 mg/dL and HCV RNA negative.
The patient had no itching or any physical complaints. A
detailed medical history ruled out a potential involve-
ment of hepatotoxic drugs, herbal remedies, dietary
supplements or alcohol consumption. Abdominal US
showed normal gallbladder and bile ducts. Ten days
after discontinuing SoC (see Table 2), AST and ALT were
14 and 13 times the u.l.n., GGT seven times the u.l.n.,
AP three times the u.l.n., and total bilirubin 6.5 mg/dL,
with no reduction of serum albumin or INR. Hepatitis B
surface antigen (HBsAg), IgM Anti-hepatitis A virus
(HAV), IgM anti-viral capsid antigen (VCA), IgM anti-
cytomegalovirus (CMV) were all negative, and HCV
RNA once more undetectable. AMA type M2 had
become positive (+++ by immunoblotting), while all
other NOSAs were negative. IgM and IgG serum levels
were 170 and 2150. The human leukocyte antigen
(HLA) profile was: DRB1-11, DRB3, DQB1-03.7
A liver biopsy (August 2006) showed severe periportal
lymphocytic piecemeal necrosis with abundant plasma
cells in the portal and periportal infiltrate and pseudo-
rosettes formed by hepatocytes, suggesting AIH. Severe
hepatocellular damage with ballooning degeneration,
apoptotic bodies, centro-zonal necrosis and small bile
duct proliferation, as highlighted by CK7 antibody, were
present, all of them characteristic of an acute – onset
(Fig. 2a–d). On the other hand, despite the AMA-M2
positivity, no features of PBC such as small bile duct
damage, portal peri-ductal granulomas and peri-portal
orcein-positive granules, or markers of chronic chola-
Table 1 Laboratory, virological and histological features
before receiving standard of care (SoC) (July 2005)
Aspartate aminotransferase
(IU/L)
48 (n.v. < 31)
Alanine aminotransferase
(IU/L)
73 (n.v. < 31)
Alkaline phosphatase (IU/L) 54 (n.v. < 104)
g-glutamil-transferase (IU/L) 14 (n.v. < 36)
Total bilirubin (mg/dL) 0.45
Total immunoglobulins
(g/dL)
0.86 (n.v. < 1.7)
Anti-HCV (EIA) Positive
Quantitative HCV-RNA
(IU/mL)
1 170 000
ANA (IFI) Negative
AMA (IFI) Negative
SMA (IFI) Negative
AMA type M2 (IB) Negative
LKM-1 (IB) Negative
LC-1 (IB) Negative
SLA/LP (IB) Negative
Histology Mild chronic HCV-related
hepatitis
Immunohistochemistry
for CK7
Normal portal bile ducts
Intrahepatic IgG/IgM
plasma cells
Low number of portal
plasma cells with an
IgM plasma cells number
<4/portal tract
AMA, antimitochondrial antibody; ANA, antinuclear antibody;
CK7, Cytokeratin 7; EIA, enzyme immunoassay; IB,
immunoblotting; IFI, indirect immunofluorescence; IgG,
immunoglobulins G; IgM, immunoglobulins M; IU,
international units; LC-1, liver cytosol type 1; LKM-1, liver
kidney/microsome type 1; n.v., normal values; SLA/LP, soluble
liver antigen/liver pancreas; SMA, smooth muscle antibody.
a b c
Figure 1 Hepatitis C virus (HCV). (a) Portal lymphocytic infiltrate with focal piecemal necrosis (Hematoxylin–Eosin staining;
200¥). (b) CK7 immunostaining evidences the presence of normal portal bile ducts (CK7 immunostaining, 200¥). (c) Immuno-
globulin M (IgM) immunostaining highlights very few IgM plasma cells (IgM immunostaining 400¥).
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tostasis were evident. Immunohistochemistry for intra-
hepatic IgG/IgM plasma cells showed a large number of
IgG plasma cells (more than 25 cells/portal tract) and an
inconspicuous presence of IgM plasma cells (less than
four cells/portal tract) in the portal tracts with an IgG/
IgM ratio >1 (Fig. 2e,f).
Assuming a diagnosis of AMA-M2 positive AIH, treat-
ment with prednisone (1 mg/kg per day) was started on
19 August 2006. Bilirubin initially peaked at 18 mg/dL at
1 week of steroid and then decreased. Upon discharge,
after 2 weeks of steroid, bilirubin was 10.2 mg/dL, AST
and ALT 3.5 and two times the u.l.n., GGT 2.5 times the
u.l.n. and AP 1.5 times the u.l.n. Steroid dosage was
tapered until discontinuation in March 2007. Mean-
while, AST/ALT and markers of cholestasis had become
normal by November 2006 and has stayed normal since
then. At last follow up visit (May 2008) AMA type M2 was
still positive (++ by immunoblotting) and HCV RNA
undetectable. All liver function tests were normal.
DISCUSSION
INDUCTION OR EXACERBATION of AIH and PBC isa known complication of SoC for chronic hepatitis C.
In our case, a definite diagnosis was not initially easy to
reach. The scoring system formulated in 1999 by the
International Autoimmune Hepatitis Group (IAIHG) is
extremely useful for the diagnosis of AIH.13 Regarding
hepatitis viral markers as negative (and this was prob-
ably correct, since HCV RNA was persistently undetect-
able), the score defined the autoimmune disease in our
patient as “probable” AIH. Nevertheless, its applicability
remains unclear in a PBC/AIH Overlap Syndrome
context, since a score of “definite” AIH can be very rarely
observed in patients with characteristic overlap syn-
drome, whereas nearly 20% of PBC subjects could be
classified with “probable” AIH overlap.14–16 Moreover,
the simplified diagnostic score recently proposed by the
IAIHG has not been validated in patients with suspected
PBC–AIH Overlap Syndrome.17
Using the simple diagnostic criteria proposed by
Chazouilleres et al.18 and recently highlighted by the
European Association for the Study of the Liver
(EASL),19 our patient could also be classified in the
context of a PBC/AIH Overlap Syndrome, as we sus-
pected before the liver biopsy just regarding the
laboratory findings and the autoantibodies profile.
Nevertheless, liver biopsy showed only the histological
features of an acute-onset AIH (severe periportal lym-
phocytic piecemeal necrosis with many plasma cells
in the portal and periportal infiltrate, presence of
hepatocytic rosettes, severe hepatocellular damage with
ballooning degeneration, apoptotic bodies and centro-
zonal necrosis) without alterations typical of PBC (bile
duct damage, portal peri-ductal granulomas and chronic
cholatostasis, as evidenced by peri-portal orcein-positive
granules).
Furthermore, the presence of numerous IgM plasma
cells in the portal tracts has been reported in PBC.20 We
Table 2 Laboratory, virological and histological features
10 days after discontinuing standard of care (SoC) (August
2006)
Aspartate aminotransferase
(IU/L)
441 (n.v. < 31)
Alanine aminotansferase
(IU/L)
408 (n.v. < 31)
Alkaline phosphatase
(IU/L)
333 (n.v. < 104)
g-glutamil-transferase
(IU/L)
248 (n.v. < 36)
Total bilirubin (mg/dL) 6,5
IgM (mg/dL) 170 (n.v. < 230)
IgG (mg/dL) 2150 (n.v. < 1600)
Qualitative HCV-RNA Negative
HBsAg Negative
IgM anti-HAV Negative
IgM anti-VCA Negative
IgM anti-CMV Negative
ANA (IFI) Negative
AMA (IFI) Negative
SMA (IFI) Negative
AMA type M2 (IB) Positive (+++)
LKM-1 (IB) Negative
LC-1 (IB) Negative
SLA/LP (IB) Negative
Histology Features of an acute-onset
AIH without signs of
CNSDC or granulomas
Immunohistochemistry
for CK7
Reactive bile duct
proliferation
Intrahepatic IgG/IgM
plasma cells
More than 25 IgG plasma
cells/portal tract and an
less than 4 IgM plasma
cells/portal
tract with an IgG/IgM
ratio >1
AMA, antimitochondrial antibody; ANA, antinuclear antibody;
CK7, Cytokeratin 7; CNSDC, chronic non-suppurative
destructive cholangitis; IB, immunoblotting; IFI, indirect
immunofluorescence; IgG, immunoglobulins G; IgM,
immunoglobulins M; IU, international units; LC-1, liver cytosol
type 1; LKM-1, liver kidney/microsome type 1; n.v., normal
values; SLA/LP, soluble liver antigen/liver pancreas; SMA,
smooth muscle antibody.
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recently reported the increase of portal IgM plasma cells
(13 IgM plasma cells/portal tract was the cut-off value)
with an IgG/IgM plasma cells ratio <1 as specific of both
PBC and “autoimmune cholangitis” patients (AIC),21 a
firmly accepted variant of PBC (AMA-negative PBC).22
Ursodeoxycholic acid (UDCA) treatment should be pre-
ferred for these patients, independently of the presence
or absence of AMA. On the other hand, all patients with
AIH, PBC/AIH or AIC/AIH overlap syndromes showed
an IgG/IgM ratio >1 and less than 13 IgM plasma cells/
portal tract, so a therapeutic approach with steroids or
steroids and UDCA should be preferred for these cases.21
In our patient, even if suggested by the AMA type
M2 positivity and by the elevation of cholestatic liver
enzymes, a diagnosis of PBC was unlikely for two
reasons. First, AMA negativity by conventional indirect
immunofluorescence at the initial diagnosis and, second,
the absence of chronic non-suppurative destructive cho-
langitis (CNSDC) or granulomas by histopathological
examinations. Moreover, the very low IgM plasma cells
number (less than four cells/portal tract) with an IgG/
IgM ratio >1 made a PBC or AIC diagnosis increasingly
unlikely. Thus, our case is devoid of any histological and
immunohistochemical features of PBC and the rapid
elevation of cholestasis markers could be more easily
explained by considering the acute setting of the disease.
On the other hand, AMA type M2 positivity is not an
exclusion criterion for “simple” AIH: a recent study23 has
reported some cases of AMA positive AIH with no clini-
cal or histologic evidence of PBC despite the continued
detection of AMAs over a follow-up of up to 27 years.
Other authors observed that clinical and histological
features of AIH were not influenced by the AMA status.24
AMA-M2 positive AIH has been reported in the litera-
ture and, to our knowledge, this is the first case in which
an acute cholestatic onset and the role of IFN as trigger
has been shown. In this setting, the relevance of the
characterization of the immunoglobulin isotype of
portal plasma cells for a more appropriate diagnosis of
autoimmune liver diseases can be emphasized.
a b c
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Figure 2 Acute-onset autoimmune hepatitis. (a) Severe periportal lymphocytic piecemeal necrosis (Hematoxylin–Eosin staining;
400¥). (b) Hepatocellular damage and ballooning degeneration of liver cells. The arrows show rosettes of liver cells (Hematoxylin–
Eosin staining; 630¥). (c) Centro-zonal necrosis, characteristic of an acute-onset (Hematoxylin–Eosin staining; 400¥). (d) CK7
highlights small bile duct proliferation in the portal-periportal areas (CK7 immunostaining, 200¥). (e,f) IgG plasma cells (e) are
much more numerous than IgM plasma cells (f) in the portal tracts (E: IgG immunostaining 630¥; F: IgM immunostaining 400¥).
Hepatology Research 2012; 42: 428–432 AIH induced by SoC for chronic hepatitis C 431
© 2012 The Japan Society of Hepatology
REFERENCES
1 Ghany MG, Strader DB, Thomas DL, Seeff LB, American
Association for the Study of Liver Diseases. Diagnosis,
management, and treatment of hepatitis C: an update.
Hepatology 2009; 49: 1335–74.
2 Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The
clinical and physiological spectrum of interferon-alpha
induced thyroiditis: toward a new classification. Hepatology
2006; 43: 661–72.
3 Wilson LE, Widman D, Dikman SH, Gorevic PD. Autoim-
mune disease complicating antiviral therapy for hepatitis C
virus infection. Semin Arthritis Rheum 2002; 32: 163–73.
4 Shindo M, Di Bisceglie AM, Hoofnagle JH. Acute exacerba-
tion of liver disease during interferon alfa therapy for
chronic hepatitis C. Gastroenterology 1992; 102: 1406–8.
5 Papo T, Marcellin P, Bernuau J, Durand F, Poynard T,
Benhamou JP. Autoimmune chronic hepatitis exacerbated
by alpha-interferon. Ann Intern Med 1992; 116: 51–3.
6 Garcia-Buey L, Garcia-Monzon C, Rodriguez S et al. Latent
autoimmune hepatitis triggered during interferon therapy
in patients with chronic hepatitis C. Gastroenterology 1995;
108: 1770–7.
7 Vispo E, Maida I, Moreno A, Barreiro P, Soriano V. Autoim-
mune hepatitis induced by pegylated interferon in an
HIV-infected patient with chronic hepatitis C. J Antimicrob
Chemother 2008; 62: 1470–2.
8 Coriat R, Podevin P. Fulminant autoimmune hepatitis after
successful interferon treatment in an HIV-HCV co-infected
patient. Int J STD AIDS 2008; 19: 208–10.
9 Kogure T, Ueno Y, Fukushima K et al. Fulminant hepatic
failure in a case of autoimmune hepatitis in hepatitis C
during peg-interferon-alpha 2b plus ribavirin treatment.
World J Gastroenterol 2007; 13: 4394–7.
10 Sezaki H, Arase Y, Tsubota A et al. Type C-chronic hepatitis
patients who had autoimmune phenomenon and devel-
oped jaundice during interferon therapy. J Gastroenterol
2003; 38: 493–500.
11 D’Amico E, Paroli M, Fratelli V et al. Primary biliary cirrho-
sis induced by interferon-alpha therapy for hepatitis C
virus infection. Dig Dis Sci 1995; 40: 2113–16.
12 Maeda T, Onishi S, Miura T et al. Exacerbation of primary
biliary cirrhosis during interferon-alpha 2b therapy for
chronic active hepatitis C. Dig Dis Sci 1995; 40: 1226–30.
13 Alvarez F, Berg PA, Bianchi FB et al. International Autoim-
mune Hepatitis Group Report: review of criteria for diag-
nosis of autoimmune hepatitis. J Hepatol 1999; 31: 929–
38.
14 Heathcote EJ. Overlap of autoimmune hepatitis and
primary biliary cirrhosis: an evaluation of a modified
scoring system. Am J Gastroenterol 2002; 97: 1090–2.
15 Talwalkar JA, Keach JC, Angulo P, Lindor KD. Overlap of
autoimmune hepatitis and primary biliary cirrhosis: an
evaluation of a modified scoring system. Am J Gastroenterol
2002; 97: 1191–7.
16 Chazouilleres O, Wendum D, Serfaty L, Rosmorduc O,
Poupon R. Long term outcome and response to therapy of
primary biliary cirrhosis–autoimmune hepatitis overlap
syndrome. J Hepatol 2006; 44: 400–6.
17 Hennes EM, Zeniya M, Czaja AJ et al. Simplified criteria for
the diagnosis of autoimmune hepatitis. Hepatology 2008;
48: 169–76.
18 Chazouilleres O, Wendum D, Serfaty L, Montembault S,
Rosmorduc O, Poupon R. Primary biliary cirrhosis–
autoimmune hepatitis overlap syndrome: clinical features
and response to therapy. Hepatology 1998; 28: 296–301.
19 European Association for the Study of the Liver. EASL
Clinical Practice Guidelines: management of cholestatic
liver diseases. J Hepatol 2009; 51: 237–67.
20 Daniels JA, Torbenson M, Anders RA et al. Immunostain-
ing of plasma cells in primary biliary cirrhosis. Am J Clin
Pathol 2009; 131: 243–9.
21 Cabibi D, Tarantino G, Barbaria F, Campione M, Craxì A,
Di Marco V. Intrahepatic IgG/IgM plasma cells ratio helps
in classifying autoimmune liver diseases. Dig Liver Dis
2010; 42: 585–92.
22 Hirshfield GM, Heathcote EJ. Antimitochondrial antibody-
negative primary biliary cirrhosis. Clin Liver Dis 2008; 12:
323–31.
23 O’Brien C, Joshi S, Feld JJ, Guindi M, Dienes HP, Heath-
cote EJ. Long-term follow-up of antimitochondrial
antibody-positive autoimmune hepatitis. Hepatology 2008;
48: 550–6.
24 Mishima S, Omagari K, Ohba K et al. Clinical implications
of antimitochondrial antibodies in type 1 autoimmune
hepatitis: a longitudinal study. Hepatogastroenterology 2008;
55: 221–7.
432 F. S. Macaluso et al. Hepatology Research 2012; 42: 428–432
© 2012 The Japan Society of Hepatology
